Vanguard Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,664,161
| Closed | -$16.6M | – | 4388 |
|
|
2025
Q2 | $16.6M | Sell |
1,664,161
-62,297
| -4% | -$502K | ﹤0.01% | 2640 |
|
|
2025
Q1 | $10.3M | Buy |
1,726,458
+92,429
| +6% | +$679K | ﹤0.01% | 2831 |
|
|
2024
Q4 | $12.5M | Sell |
1,634,029
-22,781
| -1% | -$196K | ﹤0.01% | 2825 |
|
|
2024
Q3 | $16.9M | Sell |
1,656,810
-393,196
| -19% | -$6M | ﹤0.01% | 2673 |
|
|
2024
Q2 | $30.4M | Buy |
2,050,006
+549,404
| +37% | +$7.87M | ﹤0.01% | 2362 |
|
|
2024
Q1 | $20.5M | Buy |
1,500,602
+9,660
| +0.6% | +$105K | ﹤0.01% | 2585 |
|
|
2023
Q4 | $16.3M | Sell |
1,490,942
-322,817
| -18% | -$3.2M | ﹤0.01% | 2689 |
|
|
2023
Q3 | $19.9M | Buy |
1,813,759
+40,407
| +2% | +$517K | ﹤0.01% | 2557 |
|
|
2023
Q2 | $23.5M | Buy |
1,773,352
+363
| +0% | +$5.18K | ﹤0.01% | 2525 |
|
|
2023
Q1 | $24.1M | Sell |
1,772,989
-46,041
| -3% | -$825K | ﹤0.01% | 2514 |
|
|
2022
Q4 | $35.5M | Buy |
1,819,030
+67,930
| +4% | +$1.33M | ﹤0.01% | 2337 |
|
|
2022
Q3 | $33.4M | Buy |
1,751,100
+121,514
| +7% | +$2.8M | ﹤0.01% | 2383 |
|
|
2022
Q2 | $33.6M | Buy |
1,629,586
+153,544
| +10% | +$3.64M | ﹤0.01% | 2386 |
|
|
2022
Q1 | $47.5M | Buy |
1,476,042
+415,232
| +39% | +$15.1M | ﹤0.01% | 2332 |
|
|
2021
Q4 | $49.4M | Buy |
1,060,810
+441,779
| +71% | +$14.7M | ﹤0.01% | 2364 |
|
|
2021
Q3 | $16.7M | Buy |
619,031
+104,056
| +20% | +$2.72M | ﹤0.01% | 2958 |
|
|
2021
Q2 | $13.2M | Sell |
514,975
-178,776
| -26% | -$4.26M | ﹤0.01% | 3064 |
|
|
2021
Q1 | $23.7M | Buy |
693,751
+41,973
| +6% | +$1.52M | ﹤0.01% | 2700 |
|
|
2020
Q4 | $22M | Buy |
651,778
+225,487
| +53% | +$5.97M | ﹤0.01% | 2594 |
|
|
2020
Q3 | $10.5M | Buy |
+426,291
| New | +$11.5M | ﹤0.01% | 2757 |
|
Other funds holding ITOS
Vanguard Group's ITOS Position: Q3 2025 in Review
Vanguard Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 1,664,161 shares — an estimated $16.6M sold.
Vanguard Group first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $49.4M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Vanguard Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Vanguard Group sold 1,664,161 iTeos Therapeutics shares in Q3 2025, an estimated $16.6M.
- Vanguard Group first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Vanguard Group's iTeos Therapeutics position peaked at $49.4M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.